Skip to content
RxMonitor home

Medication

Mar-Amlodipine

DIN 02371715 · Marcan Pharmaceuticals Inc Likely a generic

What it is

Active ingredients
Form and route
Tablet · Oral
Schedule
PRESCRIPTION
Authorised since
2012-10-24

Source: Health Canada — Drug Product Database. Data current as of 2026-08-12.

Products with the same active ingredient

Grouped by Health Canada’s active-ingredient group number. Products in a group do not always share a strength — check the strength above against your own. Sharing an active ingredient does not mean two products can be substituted for each other: whether a substitution is permitted is a provincial decision, and this page does not show it. Ask a pharmacist.

Ontario Drug Benefit coverage

As of 31 July 2026

General benefit Part III-A

Ontario lists this product as a general benefit under the Ontario Drug Benefit program — Part III-A of the Formulary/CDI. For someone eligible for ODB, it is covered without a drug-specific approval.

What ODB pays per unit
$0.1343

This is what the Ontario Drug Benefit program reimburses a pharmacy for one unit, as of 31 July 2026. A deductible and a co-payment sit on top of it and differ by program — ODB, the Trillium Drug Program and the seniors co-payment each work differently — so it is not the figure anyone is charged at a counter. It also says nothing about private, workplace or federal coverage.

Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.

Products Ontario considers interchangeable

As of 31 July 2026

Ontario groups these products together at 5mg Tab and will substitute one for another at a pharmacy counter in Ontario.

Ontario lists 5 further products in this group that are not currently marketed in Canada. They are not shown.

This is Ontario’s designation, under the Ontario Drug Benefit program, and it applies in Ontario. It is a different statement from the same-active-ingredient list above, which is Health Canada’s grouping and carries no substitution meaning at all. No other province’s rules are shown on this page, and a designation here is not a recommendation to switch — that is a conversation with a pharmacist or prescriber.

Source: Ontario Ministry of Health — ODB Formulary. Data current as of 2026-07-28. Ontario only. Formulary edition 4342, effective 31 July 2026.

How it is classified

Anatomical main group
Cardiovascular system
ATC code
C08CA01

The Anatomical Therapeutic Chemical code records the body system a medicine acts on and its chemical grouping. It is not a statement of what this medication treats, and nothing on this page is. For the full classification of C08CA01, see the WHO ATC/DDD Index.

Recalls and safety alerts

As of 12 August 2026
Recall:

Health Canada has published a recall or safety alert naming this product. Read it on Health Canada’s own site, and speak to a pharmacist before changing anything about how you take this medication.

  • MAR-AMLODIPINE: affected lots may contain tablet(s) of Midodrine 2.5mg tablets.

    9 February 2026Product safetyType I

    Health Canada says: Immediately check your medication bottle to ensure it only contains MAR-Amlodipine 5 mg tablets.MAR-Amlodipine 5 mg tablets are white to off-white, flat and eight-sided, with a line across the middle. One side has "210" and "5" printed on it, and the other side is blank.Midodrine 2.5 mg tablets are white, round, and marked with 'M2' on one side and have a line down the middle on the other side.If your bottle contains any unusual tablets or if you are unsure, return it to your pharmacy.If you are unable to get a replacement immediately, continue taking your medication as directed but do not take the round tablets.Contact your health care professional or call 911 if you are dizzy, have unusually high blood pressure or slow heartbeats.Seek immediate medical attention if you have chest pain, a sudden headache, an inability to move or feel a part of your body, or impaired speech.If you have questions about this recall, contact Marcan Pharmaceuticals Inc. by calling 1-855-627-2261 or by emailing info@marcanpharma.com.Report any health product-related side effects or complaints to Health Canada.Additional information for health professionals:Health care professionals, such as pharmacists, should check packages and bottles labelled MAR-Amlodipine 5 mg (amlodipine besylate) before dispensing to make sure they do not contain midodrine 2.5 mg tablets. Report any unusual bottles or other issues to the company and Health Canada.

    Matched on the product name in the notice.

This list may be incomplete. Health Canada’s recalls data carries no DIN, so notices are matched on wording alone. Search Health Canada recalls for Mar-Amlodipine → How RxMonitor matches recalls, and how often it fails

Source: Health Canada — Recalls and Safety Alerts. Data current as of 2026-08-12. Matched on product name, not on DIN — the feed carries none.

Important:

Information only — this is not medical advice. RxMonitor shows what Health Canada and provincial drug programs have published about authorised products. It does not tell you what to take, whether a medication is right for you, or what dose to use.

Always talk to a pharmacist or physician about your own medication, and never start, stop or change one based on what you read here.